Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis A vaccine: ready for prime time

B Duff1, P Duff

  • 1Division of Maternal-Fetal Medicine, University of Florida, College of Medicine, Gainesville 32610-0294, USA.

Obstetrics and Gynecology
|March 10, 1998
PubMed
Summary

Two new inactivated hepatitis A vaccines offer long-term protection for individuals over two years old. Recommended for pre-exposure prophylaxis, these vaccines demonstrate high seroconversion rates in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethnic equity in Aotearoa New Zealand's COVID-19 response: A descriptive epidemiological study.

Public health·2025
Same author

Poor working conditions and work stress among Canadian sex workers.

Occupational medicine (Oxford, England)·2017
Same author

Double Bond Position Plays an Important Role in Delta-9 Desaturation and Lipogenic Properties of Trans 18:1 Isomers in Mouse Adipocytes.

Lipids·2015
Same author

Isolation of α-linolenic acid biohydrogenation products by combined silver ion solid phase extraction and semi-preparative high performance liquid chromatography.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2015
Same author

Individual trans 18:1 isomers are metabolised differently and have distinct effects on lipogenesis in 3T3-L1 adipocytes.

Lipids·2014
Same author

Ambulatory postoperative ward-based epidural analgesia: a retrospective review of 1,147 cases.

Irish journal of medical science·2012

Area of Science:

  • Hepatology
  • Vaccinology
  • Public Health

Background:

  • Hepatitis A virus (HAV) infection poses a significant public health risk, particularly in endemic regions.
  • Effective prophylaxis is crucial for preventing HAV transmission and its associated morbidity.

Purpose of the Study:

  • To review the indications, dosages, and efficacy of two new inactivated hepatitis A vaccines.
  • To identify key populations recommended for hepatitis A vaccination.

Main Methods:

  • Review of clinical trial data and manufacturer guidelines for two inactivated hepatitis A vaccines: Vaqta and Havrix.
  • Analysis of recommended vaccination schedules for adults and children.
  • Identification of high-risk groups for HAV infection.

Related Experiment Videos

Main Results:

  • Two inactivated hepatitis A vaccines, Vaqta and Havrix, provide long-term protection and are indicated for pre-exposure prophylaxis in individuals over two years of age.
  • Specific dosing schedules are outlined for adults and children for both vaccine preparations.
  • Seroconversion rates exceeding 95% were observed in healthy children and adults, with vaccines deemed safe for use during pregnancy.

Conclusions:

  • New inactivated hepatitis A vaccines offer a safe and effective means of preventing hepatitis A infection.
  • Widespread vaccination is recommended for travelers, children in high-prevalence areas, and individuals with specific risk factors.
  • Vaccination strategies should consider age-specific dosing and schedules to maximize long-term immunity.